Therapeutic Area: Oncology

Phototherapy Restores Deficient Type I IFN Production and Enhances Antitumor Responses in Mycosis Fungoides

Yu Z, et al.
Journal of Investigative Dermatology
December 2023
immuneAccess
Authors and Affiliates
Zizi Yu 1, Pablo Vieyra-Garcia 2, Theresa Benezeder 2, Jack D Crouch 1, Ira R Kim 1, John T O'Malley 1, Phillip M Devlin 3, Ahmed Gehad 1, Qian Zhan 1, Johann E Gudjonsson 4, Mrinal K Sarkar 4, J Michelle Kahlenberg 5, Nega Gerard 1, Jessica E Teague 1, Thomas S Kupper 6, Nicole R LeBoeuf 6, Cecilia Larocca 6, Marianne Tawa 7, Bohdan Pomahac 8, Simon G Talbot 9, Dennis P Orgill 9, Peter Wolf 10, Rachael A Clark 11; 1 Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 2 Research Unit for Photodermatology, Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria. 3 Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA. 4 Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA. 5 Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. 6 Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Center for Cutaneous Oncology, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA. 7 Center for Cutaneous Oncology, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA. 8 Division of Plastic and Reconstructive Surgery, Department of Surgery, Yale School of Medicine, New Haven, Connecticut, USA. 9 Division of Plastic and Reconstructive Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 10 Research Unit for Photodermatology, Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria. Electronic address: peter.wolf@medunigraz.at. 11 Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: rclark@bwh.harvard.edu.

The prospect of universal coronavirus immunity: characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses

Soni MK, et al.
Frontiers in Immunology
November 2023
immuneAccess
Authors and Affiliates
Mithil K Soni 1, Edoardo Migliori 1, Jianing Fu 1, Amer Assal 2 3, Hei Ton Chan 3, Jian Pan 3, Prabesh Khatiwada 1, Rodica Ciubotariu 3, Michael S May 3, Marcus R Pereira 4, Valeria De Giorgi 5, Megan Sykes 1, Markus Y Mapara 1, Pawel J Muranski 1; 1 Columbia Center for Translational Immunology, Department of Medicine, Columbia University, New York, NY, United States. 2 Department of Medicine, Blood and Marrow Transplantation and Cell Therapy Program, Columbia University Irving Medical Center, New York, NY, United States. 3 Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, NY, United States. 4 Department of Medicine, Division of Infectious Disease, Columbia University College of Physicians and Surgeons, New York, NY, United States. 5 Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD, United States.

Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer

Murray JC, et al.
Clinical Cancer Research
November 2023
Authors and Affiliates
Joseph C Murray 1, Lavanya Sivapalan 2, Karlijn Hummelink 3, Archana Balan 2, James R White 4, Noushin Niknafs 5, Lamia Rhymee 2, Gavin Pereira 2, Nisha Rao 2, Benny Weksler 6, Nathan Bahary 6, Jillian Phallen 2, Alessandro Leal 7, David L Bartlett 8, Kristen A Marrone 5, Jarushka Naidoo 9, Akul Goel 10, Benjamin Levy 11, Samuel Rosner 2, Christine L Hann 2, Susan C Scott 2, Josephine Feliciano 12, Vincent K Lam 13, David S Ettinger 5, Qing Kay Li 2, Peter B Illei 14, Kim Monkhorst 15, Robert B Scharpf 9, Julie R Brahmer 2, Victor E Velculescu 2, Ali H Zaidi 6, Patrick M Forde 2, Valsamo Anagnostou 2; 1Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States. 2Johns Hopkins University School of Medicine, Baltimore, MD, United States. 3Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. 4Resphera Biosciences, Baltimore, MD, United States. 5Johns Hopkins University, Baltimore, MD, United States. 6Allegheny Health Network, Pittsburgh, PA, United States. 7Delfi Diagnostics, Baltimore, Maryland, United States. 8University of Pittsburgh, Pittsburgh, PA, United States. 9Johns Hopkins University School of Medicine, Baltimore, United States. 10California Institute of Technology, United States. 11Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Washington, D.C., United States. 12Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, United States. 13Johns Hopkins, Baltimore, MD, United States. 14Johns Hopkins University School of Medicine, Baltimore, Maryland, United States. 15Netherlands Cancer Institute, Amsterdam, Netherlands.

Characterization of immune cell populations of cutaneous neurofibromas in neurofibromatosis 1

Kallionpää RA, et al.
November 2023
Authors and Affiliates
Roope A Kallionpää 1, Sirkku Peltonen 2, Kim My Le 3, Eija Martikkala 3, Mira Jääskeläinen 3, Elnaz Fazeli 4, Pilvi Riihilä 5, Pekka Haapaniemi 6, Anne Rokka 6, Marko Salmi 7, Ilmo Leivo 3, Juha Peltonen 8; 1 Institute of Biomedicine, University of Turku, Turku, Finland; FICAN West Cancer Centre, University of Turku and Turku University Hospital, Turku, Finland. 2 Department of Dermatology and Venereology, University of Turku, Turku, Finland; Department of Dermatology, Turku University Hospital, Turku, Finland; Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Dermatology and Venereology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Dermatology and Allergology, University of Helsinki, Helsinki, Finland; Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland. 3 Institute of Biomedicine, University of Turku, Turku, Finland. 4 Institute of Biomedicine, University of Turku, Turku, Finland; Biomedicum Imaging Unit, Faculty of Medicine and HiLIFE, University of Helsinki, Helsinki, Finland. 5 Department of Dermatology and Venereology, University of Turku, Turku, Finland; Department of Dermatology, Turku University Hospital, Turku, Finland; FICAN West Cancer Research Laboratory, University of Turku and Turku University Hospital, Turku, Finland. 6 Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland. 7 Institute of Biomedicine, University of Turku, Turku, Finland; MediCity Research Laboratory, and InFLAMES Research Flagship Center, University of Turku, Turku, Finland. 8 Institute of Biomedicine, University of Turku, Turku, Finland; FICAN West Cancer Centre, University of Turku and Turku University Hospital, Turku, Finland. Electronic address: juhpel@utu.fi.

The tumor microenvironment state associates with response to HPV therapeutic vaccination in patients with respiratory papillomatosis

Norberg SM, et al.
Science Translational Medicine
November 2023
Authors and Affiliates
Scott M Norberg 1, Ke Bai 2, Cem Sievers 2, Yvette Robbins 2, Jay Friedman 2, Xinping Yang 2, Meg Kenyon 1, Elizabeth Ward 3, Jeffrey Schlom 1, James Gulley 1, Amy Lankford 3, Roshanak Semnani 3, Helen Sabzevari 3, Douglas E Brough 3, Clint T Allen 1,2; 1 Center for Immune-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. 2 Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. 3 Precigen Inc., Germantown, MD 20876, USA.

Heterozygote advantage at HLA class I and II loci and reduced risk of colorectal cancer

Tsai Y, et al.
Frontiers in Immunology
November 2023
Authors and Affiliates
Ya-Yu Tsai 1, Chenxu Qu 2, Joseph D Bonner 3, Rebeca Sanz-Pamplona 4 5 6 7, Sidney S Lindsey 3, Marilena Melas 8, Kevin J McDonnell 3, Gregory E Idos 3, Christopher P Walker 3, Kevin K Tsang 3, Diane M Da Silva 2, Ferran Moratalla-Navarro 4 5 6 9, Asaf Maoz 10, Hedy S Rennert 11, W Martin Kast 2, Joel K Greenson 12, Victor Moreno 4 5 6 9, Gad Rennert 11, Stephen B Gruber 3, Stephanie L Schmit 1 13; 1Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH, United States. 2Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, United States. 3Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA, United States. 4Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain. 5ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain. 6Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain. 7Hospital Universitario Lozano Blesa, Aragon Health Research Institute (IISA), ARAID Foundation, Aragon Government, Zaragoza, Spain. 8Molecular Diagnostics, New York Genome Center, New York, NY, United States. 9Department of Clinical Sciences, Faculty of Medicine and Health Sciences and Universitat de Barcelona Institute of Complex Systems (UBICS), University of Barcelona, Barcelona, Spain. 10Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States. 11B. Rappaport Faculty of Medicine, Technion and the Association for Promotion of Research in Precision Medicine (APRPM), Haifa, Israel. 12Department of Pathology, University of Michigan, Ann Arbor, MI, United States. 13Population and Cancer Prevention Program, Case Comprehensive Cancer Center, Cleveland, OH, United States.

Systematic discovery of neoepitope-HLA pairs for neoantigens shared among patients and tumor types

Gurung HR, et al.
Nature Biotechnology
November 2023
Authors and Affiliates
Hem R Gurung 1, Amy J Heidersbach 1, Martine Darwish 1, Pamela Pui Fung Chan 1, Jenny Li 1, Maureen Beresini 1, Oliver A Zill 1, Andrew Wallace 1, Ann-Jay Tong 1, Dan Hascall 1, Eric Torres 1, Andy Chang 1, Kenny 'Hei-Wai' Lou 1, Yassan Abdolazimi 1, Christian Hammer 1, Ana Xavier-Magalhães 1, Ana Marcu 1, Samir Vaidya 1, Daniel D Le 1, Ilseyar Akhmetzyanova 1, Soyoung A Oh 1, Amanda J Moore 2, Uzodinma N Uche 2, Melanie B Laur 2, Richard J Notturno 2, Peter J R Ebert 2, Craig Blanchette 3, Benjamin Haley 4, Christopher M Rose 5; 1 Genentech, South San Francisco, CA, USA. 2 Adaptive Biotechnologies, Seattle, WA, USA. 3 Genentech, South San Francisco, CA, USA. cdblanchette@gmail.com. 4 Genentech, South San Francisco, CA, USA. ben.haley@gmail.com. 5 Genentech, South San Francisco, CA, USA. rose.christopher@gene.com.

Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring

Colbert LE, et al.
Cancer Cell
November 2023
immuneAccess
Authors and Affiliates
Lauren E Colbert 1, Molly B El Alam 2, Rui Wang 2, Tatiana Karpinets 3, David Lo 2, Erica J Lynn 2, Timothy A Harris 2, Jacob H Elnaggar 4, Kyoko Yoshida-Court 2, Katarina Tomasic 2, Julianna K Bronk 2, Julie Sammouri 2, Ananta V Yanamandra 5, Adilene V Olvera 6, Lily G Carlin 6, Travis Sims 7, Andrea Y Delgado Medrano 2, Tatiana Cisneros Napravnik 2, Madison O'Hara 8, Daniel Lin 2, Chike O Abana 2, Hannah X Li 2, Patricia J Eifel 2, Anuja Jhingran 2, Melissa Joyner 2, Lilie Lin 2, Lois M Ramondetta 7, Andrew M Futreal 3, Kathleen M Schmeler 7, Geena Mathew 2, Stephanie Dorta-Estremera 9, Jianhua Zhang 3, Xiaogang Wu 3, Nadim J Ajami 10, Matthew Wong 10, Cullen Taniguchi 2, Joseph F Petrosino 11, K Jagannadha Sastry 8, Pablo C Okhuysen 6, Sara A Martinez 12, Lin Tan 12, Iqbal Mahmud 12, Philip L Lorenzi 12, Jennifer A Wargo 13, Ann H Klopp 2; 1Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: lcolbert@mdanderson.org. 2Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 3Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 4Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; LSU School of Medicine, Louisiana State University, Baton Rouge, LA 70803, USA. 5Department of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 6Departments of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 7Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 8Department of Thoracic Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 9Department of Microbiology and Medical Zoology, University of Puerto Rico, San Juan, PR 00921, USA. 10Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Platform for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 11Department of Molecular Virology and Microbiology, The Alkek Center for Metagenomics and Microbiome Research, Baylor College of Medicine, Houston, TX 77030, USA. 12Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 13Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; LSU School of Medicine, Louisiana State University, Baton Rouge, LA 70803, USA; Platform for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

A H3K27M-targeted vaccine in adults with diffuse midline glioma

Grassl N, et al.
Nature Medicine
November 2023
Authors and Affiliates
Niklas Grassl 1,2,3, Isabel Poschke 1,4, Katharina Lindner 1,4, Lukas Bunse 1,2,3, Iris Mildenberger 1,2,3, Tamara Boschert 1,4,5, Kristine Jähne 1,2,3, Edward W Green 1,2,3, Ingrid Hülsmeyer 1,4, Simone Jünger 1,4, Tobias Kessler 6,7, Abigail K Suwala 8,9, Philipp Eisele 2, Michael O Breckwoldt 1,3,10, Peter Vajkoczy 11, Oliver M Grauer 12, Ulrich Herrlinger 13, Joerg-Christian Tonn 14, Monika Denk 15, Felix Sahm 8,9, Martin Bendszus 10, Andreas von Deimling 8,9, Frank Winkler 6,7, Wolfgang Wick 6,7, Michael Platten 16,17,18,19,20, Katharina Sahm 21,22,23; 1 DKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 2 Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Mannheim, Germany. 3 DKFZ-Hector Cancer Institute at University Medical Center Mannheim, Mannheim, Germany. 4 Immune Monitoring Unit, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany. 5 Helmholtz Institute for Translational Oncology (HI-TRON) Mainz, German Cancer Research Center, Mainz, Germany. 6 Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany. 7 National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany. 8 Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany. 9 DKTK Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 10 Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany. 11 Department of Neurosurgery, Charité-Universitätsmedizin Berlin, Berlin, Germany. 12 Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany. 13 Division of Clinical Neurooncology, Department of Neurology, University Hospital Bonn, University of Bonn, Bonn, Germany. 14 Department of Neurosurgery, University of Munich LMU, Munich, Germany. 15 Institute of Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany. 16 DKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. m.platten@dkfz-heidelberg.de. 17 Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Mannheim, Germany. m.platten@dkfz-heidelberg.de. 18 DKFZ-Hector Cancer Institute at University Medical Center Mannheim, Mannheim, Germany. m.platten@dkfz-heidelberg.de. 19 Immune Monitoring Unit, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany. m.platten@dkfz-heidelberg.de. 20 Helmholtz Institute for Translational Oncology (HI-TRON) Mainz, German Cancer Research Center, Mainz, Germany. m.platten@dkfz-heidelberg.de. 21 DKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. k.sahm@dkfz-heidelberg.de. 22 Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Mannheim, Germany. k.sahm@dkfz-heidelberg.de. 23 DKFZ-Hector Cancer Institute at University Medical Center Mannheim, Mannheim, Germany.